Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VERICIGUAT
- A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
- SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
- A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
- The Anti-myocardial Fibrosis Effect of Vericiguat in HFrEF
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
- Impact of Vericiguat on Hemodynamics of Heart Failure
- Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome
- A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Ch
- The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
- A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
- A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immed
- A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
- A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
- Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
- Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
- Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients
- Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects
- A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
- Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Clinical trials list
click for details